As the systemic mastocytosis treatment landscape evolves, Ayvakit may face challenges from new entrants or improved therapies from competitors. While Ayvakit has shown significant efficacy and safety ...

What risks does Blueprint face in achieving profitability ... in overall survival for patients with Advanced Systemic Mastocytosis (ASM), with an 81% risk reduction of death in first-line ...

What risks does Blueprint face in achieving profitability ... have shown significant improvements in overall survival for patients with Advanced Systemic Mastocytosis (ASM), with an 81% risk reduction ...

Discover 8 ways mast cell activation syndrome causes widespread symptoms from digestive issues to brain fog, often mistaken ...

Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM ... the company may face hurdles in achieving optimal financial returns.

Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM ... the company may face hurdles in generating optimal returns from its assets.

North Point High School art teacher Theresa Alo was recognized earlier this month at the RareARTist reception, an event that showcases artwork from individuals impacted by rare diseases.

As a result, patients face potentially debilitating symptoms ... to conduct the Perceptions Reality and Insights on Systemic Mastocytosis (PRISM) study. This multi-country assessment has ...